Keyphrases
Acute Lymphoblastic Leukemia
9%
ADAR1
6%
Adenosine Deaminase Acting on RNA
6%
Adoptive Cell Therapy
50%
Adoptive Cell Transfer
21%
Adoptive Immunotherapy
6%
Adoptive Transfer
13%
Adoptive Transfer Therapy
6%
Anti-CD19 chimeric Antigen Receptor T Cells
9%
Anti-melanoma
7%
Antitumor
11%
Autologous Tumors
10%
Autoreactive T Cells
9%
B-cell Malignancies
7%
Carcinoembryonic Antigen
9%
CD19
10%
CD19 chimeric Antigen Receptor T Cells
14%
CD28
11%
CD40
6%
CD8+ T Cells
7%
CEACAM1
16%
Cell Adhesion Molecule 1 (CADM1)
12%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Chimeric Antigen Receptor T-cell Therapy
16%
Clinical Response
14%
Complete Response
6%
Constitutively Active
8%
Effector Function
8%
Genetic Modification
10%
High-dose interleukin-2
6%
Immune Resistance
6%
Intercellular Adhesion molecule-1 (ICAM-1)
7%
Interferon-α (IFN-α)
6%
Interleukin-2
12%
Ipilimumab
6%
Large B-cell Lymphoma
6%
Lymphocyte Culture
11%
Melanoma
43%
Melanoma Cells
31%
Melanoma Patients
19%
Metastatic Melanoma
50%
MicroRNA
10%
MRNA Electroporation
6%
Normal Human
9%
Overall Survival
6%
Relapsed or Refractory Acute Myeloid Leukemia
7%
T Cell Activation
10%
T Cells
54%
Tumor
11%
Tumor-infiltrating Lymphocytes
100%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
12%
Adoptive Transfer
14%
B-Cell Lymphoma
6%
Cancer
6%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 1
13%
Cell Therapy
35%
Chimeric Antigen Receptor
20%
Chimeric Antigen Receptor T-Cell
38%
Chimeric Antigen Receptor T-Cell Immunotherapy
11%
Cytotoxic T-Cell
7%
Diseases
9%
Drug Megadose
7%
Immunotherapy
29%
Infusion
9%
Integrin
6%
Interleukin 2
15%
Large-Cell Lymphoma
7%
Leukapheresis
5%
Lymphocyte
7%
Lymphocyte Culture
6%
Malignant Neoplasm
8%
Melanoma
54%
Melanoma Cell
12%
Messenger RNA
5%
Metastatic Melanoma
41%
microRNA
6%
Neoplasm
39%
Overall Survival
6%
Receptor
9%
Secretion (Process)
6%
T Cell
49%
T Lymphocyte
8%
Transfer Cell
14%
Tumor Infiltrating Lymphocyte
58%
Tumor Necrosis Factor
6%
Immunology and Microbiology
Adenosine Deaminase
6%
Adjuvant
5%
Adoptive Immunotherapy
6%
Antineoplastic Activity
5%
B Cell
13%
Carcinoembryonic Antigen
9%
CD19
26%
CD28
9%
CEACAM1
16%
Cell Adhesion Molecule 1
12%
Cell Line
10%
Chimeric Antigen Receptor
15%
Chimeric Antigen Receptor T-Cell
24%
Chimeric Antigen Receptor T-Cell Therapy
12%
Cytokine
8%
Cytotoxic T-Cell
8%
Cytotoxicity
5%
DNA Modification
7%
Downregulation
5%
Electroporation
6%
Immunocompetent Cell
6%
Immunotherapy
35%
interferon
6%
Interleukin 2
14%
Ipilimumab
5%
Lymphocyte
11%
Lymphocyte Culture
7%
Melanoma Cell
32%
Natural Killer Cell
7%
Neoantigen
8%
Normal Human
6%
Overall Survival
6%
Secretion (Process)
10%
T Cell
72%
T Cell Receptor
5%
Transfer Cell
19%
Tumor Cell
5%
Tumor Necrosis Factor
7%
Tumor-Associated Macrophage
16%
Tumor-Infiltrating Lymphocytes
65%
